Published 11/02/2009 by News-Medical.Net
BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients
Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.
The poster included data on 56 patients in...
Share this
What others report on the same story